Ved 18 måneder, i et igangværende langtids- sammenligningsstudie, var rosiglitazon, i kombinationsbehandling med metformin eller sulfonylurinstof, ikke- inferiør over for kombinationen af sulfonylurinstof plus metformin til sænkning af HbAlc.
At 18 months, in an ongoing long term comparator study, rosiglitazone in dual oral therapy with metformin or a sulphonylurea was non-inferior to the combination of sulphonylurea plus metformin for lowering HbA1c.